Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | QPCT | Q16769 | 1/20 | 0.50 |
| ▸ | VEGFA | P15692 | 1/20 | 0.50 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
| ▸ | DRD4 | P21917 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3181153 | 0.91 | SMN1; SMN2 (0.57) | SMN1; SMN2LMNAQPCTVEGFAEGLN1 | |
| SCHEMBL14416010 | 0.85 | SMN1; SMN2 (0.56) | SMN1; SMN2LMNAQPCTVEGFAEGLN1 | |
| SCHEMBL8443968 | 0.84 | HMOX1 (0.65) | SMN1; SMN2LMNAQPCTVEGFAEGLN1 | |
| SCHEMBL14416009 | 0.84 | CYP19A1 (0.67) | SMN1; SMN2LMNAQPCTCYP11B1CYP19A1 | |
| SCHEMBL6571544 | 0.84 | CYP1A2 (0.61) | SMN1; SMN2LMNAQPCTALDH1A1CYP11B1 | |
| SCHEMBL2475754 | 0.84 | QPCT (0.67) | SMN1; SMN2QPCTVEGFAEGLN1CYP11B1 | |
| SCHEMBL8949305 | 0.81 | NOS1 (0.59) | SMN1; SMN2LMNAQPCTVEGFAEGLN1 | |
| SCHEMBL14416015 | 0.81 | MEN1 (0.61) | QPCTALDH1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL3183135 | 0.81 | CYP3A4 (0.53) | SMN1; SMN2LMNAQPCTVEGFAEGLN1 | |
| SCHEMBL8447144 | 0.81 | CYP2A6 (0.56) | SMN1; SMN2QPCTALDH1A1CYP11B1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100022769-A1 | NOVEL POLYNITROGENATED SYSTEMS AS ANTI-HIV AGENTS | INSTITUT QUIMIC DE SARRIA CETS (ES) | 2010-01-28 | — | — | US | disclosed |
| EP-2100890-A1 | NOVEL POLYNITROGENATED SYSTEMS AS ANTI-HIV AGENTS | Institut Quimic De Sarria Cets (ES) | 2009-09-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022769-A1 | NOVEL POLYNITROGENATED SYSTEMS AS ANTI-HIV AGENTS | MSR1, CCR5, CD4 | SMN1; SMN2 3105/4885LMNA 4118/4885QPCT 2033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.